CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib

Abstract Cyclin D‐CDK4/6 are the first CDK complexes to be activated in the G1 phase in response to oncogenic pathways. The specific CDK4/6 inhibitor PD0332991 (palbociclib) was recently approved by the FDA and EMA for treatment of advanced ER‐positive breast tumors. Unfortunately, no reliable predi...

詳細記述

書誌詳細

主要な著者:	Eric Raspé, Katia Coulonval, Jaime M Pita, Sabine Paternot, Françoise Rothé, Laure Twyffels, Sylvain Brohée, Ligia Craciun, Denis Larsimont, Véronique Kruys, Flavienne Sandras, Isabelle Salmon, Steven Van Laere, Martine Piccart, Michail Ignatiadis, Christos Sotiriou, Pierre P Roger
フォーマット:	Artigo
言語:	Inglês
出版事項:	Springer Nature 2017-05-01
シリーズ:	EMBO Molecular Medicine
主題:	CDK4/6 inhibitors breast cancer cyclin‐dependent kinase 4 PD0332991 sensitivity biomarker
オンライン･アクセス:	https://doi.org/10.15252/emmm.201607084
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!